Authors: Waldherr, C Pless, M Maecke, HR Haldemann, A Mueller-Brand, J

Citation: C. Waldherr et al., The clinical value of [Y-90-DOTA]-D-Phe(1)-Tyr(3)-octreotide (Y-90-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study, ANN ONCOL, 12(7), 2001, pp. 941-945

Authors: Waldherr, C Schumacher, T Pless, M Crazzolara, A Maecke, HR Nitzsche, EU Haldemann, A Mueller-Brand, J

Citation: C. Waldherr et al., Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [Y-90]-DOTA-D-Phe(1)-Tyr(3)-octreotide: a pilot study, NUCL MED C, 22(6), 2001, pp. 673-678

Authors: Waldherr, C Haldemann, A Maecke, HR Crazzolara, A Mueller-Brand, J

Citation: C. Waldherr et al., Exceptional results in neuroendocrine-metastases-caused paraplegia treatedwith [Y-90-DOTA]-D-Phe(1)-Tyr(3)-octreotide (Y-90-DOTATOC), a radiolabelled somatostatin analogue, CL ONCOL-UK, 12(2), 2000, pp. 121-123

Authors: Waldherr, C Otte, A Mueller-Brand, J

Citation: C. Waldherr et al., Ga-67 scintigraphy in a patient with B-cell lymphoma, CLIN NUCL M, 25(5), 2000, pp. 389-389

Authors: Bettschart, RW Waldherr, C Wiesner, W Bingisser, R

Citation: Rw. Bettschart et al., Pretibial pain and swellings, SCHW MED WO, 130(15), 2000, pp. 558-558

Authors: Waldherr, C Otte, A Haldemann, A Muller-Brand, J

Citation: C. Waldherr et al., The Marine-Lenhart-syndrome: A case reflection upon 18 years, NUKLEARMED, 38(8), 1999, pp. 345-348